Dr. Daniel Sipple is board certified in physical medicine and rehabilitation with sub-specialty board certification in pain medicine. He trained at the Rehabilitation Institute of Chicago, now the Shirley Ryan Ability Lab, the #1 rated rehabilitation hospital in US News and World Report over 20 years running. He served on faculty at Northwestern University Medical School while working at RIC’s American Academy of Pain Medicine Center of Excellence. He subsequently practiced in Denver Colorado for two years, working along side former team physicians of the Denver Broncos and Colorado Rockies. Thereafter, at the Mayo Clinic in Eau Claire, Wisconsin via the Pain Clinic of NW Wisconsin. He served at the medical director the Health East Spine Center, and service line medical director over Neurosurgery, Behavioral Health, Pain and Spine for the health system. Dr. Sipple is the co-founder of InSitu Biologics, and co-inventor of INSB 200, sustained release non-opiate pain killer for post operative pain set to enter phase I FDA clinical trials in 2022. He is the patient holder in safe needle technology and the founder of Acies Medical. He served on the Board of Directors for the Society for Brain Mapping and Therapeutics, a NASA Spinout, and part of President Obama’s BRAIN Initiative. In that capacity has presented to the United States Congress, the California Legislature, the White House, along with world leaders at the Neuroscience 20 Summit in conjunction with the G20 in Buenos Aires, Argentina and Osaka Japan. SBMT think tank papers that Dr. Sipple has co-authored have been recognized by the WHO, including a leading position paper on COVID 19. SBMT’s Brain Technology Park Initiative seeks to place the United States as global leaders in neurotech, and is supported by DARPA, NASA, Los Alamos National Labs, Lawrence Livermore National Labs, and more.